Amide is at the forefront of a new biotech industry—fully synthetic proteins—that boasts the combinatorial flexibility of small molecules, alongside the physiological advantages of biologics. As the experts in this new field, we champion the protein therapeutic 2.0 market.
Amide was founded on the seminal inventions of Prof. Brad Pentelute enabling on-demand protein synthesis including non-natural chemical modifications - providing unique protein functionality (affinity, stability, bioavailability, cell membrane penetration) and reduced immunogenicity. Engineered synthetic proteins are coupled with our artificial intelligence (AI) tools to predict performance characteristics of our assets at a scale unattainable with traditional methods for protein synthesis and post-translational modifications.
Our pipeline aims to relieve patient suffering and modify the disease course of autoimmune diseases, inflammatory disorders, cancers and COVID19.